Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.7150/thno.49713 http://scihub22266oqcxt.onion/10.7150/thno.49713 33391477!7681075!33391477     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Theranostics 2021 ; 11 (1): 316-329 Nephropedia Template TP {{tp|p=33391477|t=2021. Immunopathogenesis and treatment of cytokine storm in COVID-19 |pdf=|usr=}}{{33391477}} gab.com Text Immunopathogenesis and treatment of cytokine storm in COVID-19 JO: Theranostics http://www.kidney.de/pget.php?&tw=1&pmid=33391477 #FOAvip Severe coronavirus disease 2019 (COVID-19) is characterized by systemic hyper-inflammation, acute respiratory distress syndrome, and multiple organ failure. Cytokine storm refers to a set of clinical conditions caused by excessive immune reactions and has been recognized as a leading cause of severe COVID-19. While comparisons have been made between COVID-19 cytokine storm and other kinds of cytokine storm such as hemophagocytic lymphohistiocytosis and cytokine release syndrome, the pathogenesis of cytokine storm has not been clearly elucidated yet. Recent studies have shown that impaired response of type-1 IFNs in early stage of COVID-19 infection played a major role in the development of cytokine storm, and various cytokines such as IL-6 and IL-1 were involved in severe COVID-19. Furthermore, many clinical evidences have indicated the importance of anti-inflammatory therapy in severe COVID-19. Several approaches are currently being used to treat the observed cytokine storm associated with COVID-19, and expectations are especially high for new cytokine-targeted therapies, such as tocilizumab, anakinra, and baricitinib. Although a number of studies have been conducted on anti-inflammatory treatments for severe COVID-19, no specific recommendations have been made on which drugs should be used for which patients and when. In this review, we provide an overview of cytokine storm in COVID-19 and treatments currently being used to address it. In addition, we discuss the potential therapeutic role of extracorporeal cytokine removal to treat the cytokine storm associated with COVID-19. Twit Text FOAVip Immunopathogenesis and treatment of cytokine storm in COVID-19 ????Theranostics http://www.kidney.de/pget.php?&tw=1&pmid=33391477 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33391477 #FOAvip English Wikipedia <ref>{{Cite pmid|33391477}}</ref> Immunopathogenesis and treatment of cytokine storm in COVID-19 #MMPMID33391477 Kim JS; Lee JY; Yang JW; Lee KH; Effenberger M; Szpirt W; Kronbichler A; Shin JI Theranostics 2021[]; 11 (1): 316-329 PMID33391477show ga Severe coronavirus disease 2019 (COVID-19) is characterized by systemic hyper-inflammation, acute respiratory distress syndrome, and multiple organ failure. Cytokine storm refers to a set of clinical conditions caused by excessive immune reactions and has been recognized as a leading cause of severe COVID-19. While comparisons have been made between COVID-19 cytokine storm and other kinds of cytokine storm such as hemophagocytic lymphohistiocytosis and cytokine release syndrome, the pathogenesis of cytokine storm has not been clearly elucidated yet. Recent studies have shown that impaired response of type-1 IFNs in early stage of COVID-19 infection played a major role in the development of cytokine storm, and various cytokines such as IL-6 and IL-1 were involved in severe COVID-19. Furthermore, many clinical evidences have indicated the importance of anti-inflammatory therapy in severe COVID-19. Several approaches are currently being used to treat the observed cytokine storm associated with COVID-19, and expectations are especially high for new cytokine-targeted therapies, such as tocilizumab, anakinra, and baricitinib. Although a number of studies have been conducted on anti-inflammatory treatments for severe COVID-19, no specific recommendations have been made on which drugs should be used for which patients and when. In this review, we provide an overview of cytokine storm in COVID-19 and treatments currently being used to address it. In addition, we discuss the potential therapeutic role of extracorporeal cytokine removal to treat the cytokine storm associated with COVID-19. |Anti-Inflammatory Agents/pharmacology/*therapeutic use[MESH] |Antibodies, Monoclonal, Humanized/pharmacology/therapeutic use[MESH] |Azetidines/pharmacology/therapeutic use[MESH] |COVID-19 Drug Treatment[MESH] |COVID-19/*complications/immunology/virology[MESH] |Clinical Trials as Topic[MESH] |Cytokine Release Syndrome/drug therapy/*immunology[MESH] |Cytokines/antagonists & inhibitors/immunology/*metabolism[MESH] |Humans[MESH] |Immunosuppressive Agents/pharmacology/*therapeutic use[MESH] |Interleukin 1 Receptor Antagonist Protein/pharmacology/therapeutic use[MESH] |Janus Kinases/antagonists & inhibitors/metabolism[MESH] |Purines/pharmacology/therapeutic use[MESH] |Pyrazoles/pharmacology/therapeutic use[MESH] |SARS-CoV-2/immunology[MESH] |STAT Transcription Factors/antagonists & inhibitors/metabolism[MESH] |Severity of Illness Index[MESH] |Signal Transduction/drug effects/immunology[MESH] |Sulfonamides/pharmacology/therapeutic use[MESH]Immunopathogenesis and treatment of cytokine storm in COVID-19 (epmc).pdf DeepDyve Pubget Overpricing